Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”
Hepatology Research · 2026-11 · 56 (11) · 1763-1764
DOI: 10.1111/hepr.70227 ↗Kurz gefasst
Leserbrief in der Zeitschrift Hepatology Research, online erschienen am 24.06.2026. Verfasst von Yingzhe Zhang. Beteiligte Einrichtung: Department of Pharmacy, Shaoxing Central Hospital, Shaoxing University, Shaoxing, China. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pharmacy, Shaoxing Central Hospital, Shaoxing University, Shaoxing, China.
Zitieren
APA
Zhang, Y. (2026). Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”. Hepatology Research, 56(11), 1763-1764. https://doi.org/10.1111/hepr.70227
Vancouver
Zhang Y. Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”. Hepatology Research. 2026;56(11):1763-1764. doi:10.1111/hepr.70227
BibTeX
@article{Zhang2026,
author = {Zhang, Yingzhe},
title = {Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {11},
pages = {1763--1764},
doi = {10.1111/hepr.70227}
}
EUVIMED